Thyroid receptor ligands. Part 8: Thyromimetics derived from N-acylated-α-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 15, 2007, Pages 4131-4134

  Garg, Neeraj ^a   Li, Yi Lin ^a   Garcia Collazo, Ana Maria ^a   Litten, Chris ^a   Ryono, Denis E ^b   Zhang, Minsheng ^d   Caringal, Yolanda ^b   Brigance, Robert P ^b   Meng, Wei ^b   Washburn, William N ^b   Agback, Peter ^a   Mellström, Karin ^a   Rehnmark, Stefan ^a   Rahimi Ghadim, Mahmoud ^a   Norin, Thomas ^a   Grynfarb, Marlena ^a   Sandberg, Johnny ^a   Grover, Gary ^c   Malm, Johan ^a  

^a Karo Bio   (Sweden)

^b BRISTOL MYERS SQUIBB   (United States)

^c Eurofins Medinet Inc   (United States)

^d PFIZER INC   (United States)

Author keywords

Amino acid; Binding assay; Cholesterol; Cholesterol fed rat model; KB 141; Tachycardia; Thyroid stimulating hormone; Thyromimetic; TR selective

Indexed keywords

AMINO ACID DERIVATIVE; N ACYLATED ALPHA AMINO ACID DERIVATIVE; RADIOLIGAND; THYROMIMETIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BINDING ASSAY; CELL ASSAY; CHEMICAL STRUCTURE; HUMAN; RECEPTOR BINDING; TACHYCARDIA;

AMINO ACIDS; ANIMALS; CHO CELLS; CHOLESTEROL, DIETARY; CRICETINAE; CRICETULUS; LIGANDS; MOLECULAR MIMICRY; PHENYL ETHERS; PHENYLACETATES; RADIOLIGAND ASSAY; RATS; RECEPTORS, THYROID HORMONE;

RATTUS;

EID: 34447105124     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.05.049     Document Type: Article

References (16)

1. Talbert R.L. Am. J. Health. Syst. Pharm. 60 (2003) S3 quiz S25
2. Friday K.E. Exp. Biol. Med. (Maywood). 228 (2003) 769
3. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. J. Am. Coll. Cardiol. 44 (2004) 720
4. Malm J. Curr. Pharm. Des. 10 (2004) 3522
5. Webb P. Exp. Opin. Invest. Drugs 13 (2004) 489
6. Malm J., Grover G.J., and Färnegårdh M. Mini-Rev. Med. Chem. 7 (2007) 79
7. Yokoyama N., Walker G.N., Main A.J., Stanton J.L., Morrissey M.M., Boehm C., Engle A., Neubert A.D., Wasvary J.M., Stephan Z.F., and Steele R.E. J. Med. Chem. 38 (1995) 695
8. Barlow J.W., Raggatt L.E., Lim C., Kolliniatis E., Topliss D.J., and Stockigt J.R. Acta Endocrinol. 124 (1991) 37
9. Ye L., Li Y.-L., Mellström K., Bladh L.-G., Koehler K., Garg N., Garcia Collazo A.M., Litten C., Husman B., Persson K., Ljunggren J., Grover G., Sleph P.G., George R., and Malm J. J. Med. Chem. 46 (2003) 1580
10. Grover G.J., Mellström K., Ye L., Malm J., Li Y.-L., Bladh L.-G., Sleph P.G., Smith M.A., George R., Vennström B., Mookhtiar K., Horvath R., Speelman J., Egan D., and Baxter J.D. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 10067
11. Grover G.J., and Malm J. Drug Discovery Today, Ther. Strat. 2 (2005) 137
12. TR-binding assay, vector constructs, generation of reporter cell lines (TRAF), and assay procedures have been described in detail in Ref. 4 and references therein.
13. 4′-hydroxyl group is still unionized.
14. For the use of the TRAF-assay in 'antagonist-mode', see:. Carlsson B., Singh B.N., Temciuc M., Nilsson S., Li Y.-L., Mellin C., and Malm J. J. Med. Chem 45 (2002) 623
15. Koehler K., Gordon S., Brandt P., Carlsson B., Bäcksbro-Saeidi A., Apelqvist T., Agback P., Grover G.J., Nelson W., Grynfarb M., Färnegårdh M., Rehnmark S., and Malm J. J. Med. Chem. 49 (2006) 6635
16. Hedfors Å., Appelqvist T., Carlsson B., Bladh L.-B., Litten C., Agback P., Grynfarb M., Koehler K.F., and Malm J. J. Med. Chem. 48 (2005) 3114